Article history: Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparti- Received 4 November 2011 cles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The Received in revised form mean particle size and mean zeta potential of CUR–DOX–PBCA-NPs were 133 ± 5.34 nm in diam- 27 December 2011 eter and +32.23 ± 4.56 mV, respectively. The entrapment efﬁciencies of doxorubicin and curcumin Accepted 9 January 2012 were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efﬁcacy of the Available online 17 January 2012 formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2-yl] 2,5- diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded Keywords: PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs Curcumin (DOX–PBCA-NPs + CUR–PBCA-NPs), which was slightly higher than that of the free drug combination Doxorubicin (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR–PBCA-NPs or Poly(butyl cyanoacrylate) nanoparticles Multidrug resistance CUR + DOX–PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efﬁcacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced
International Journal of Pharmaceutics – Elsevier
Published: Apr 15, 2012
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud